| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Angelica Montini, Alex Iranzo, Pietro Cortelli, Carles Gaig, Amaia Muñoz-Lopetegi, Federica Provini, Joan Santamari. Scoring sleep in neurodegenerative diseases: A pilot study in the synucleinopathies. Sleep medicine. vol 110. 2023-09-07. PMID:37678074. |
our aim was to develop a scoring method that incorporates the stages previously applied in dementia with lewy bodies (dlb), anti-iglon5 disease, and fatal insomnia, and to test it in patients with alpha-synucleinopathies. |
2023-09-07 |
2023-10-07 |
Not clear |
| Laura Arnaldo, Aintzane Urbizu, Mònica Serradell, Carles Gaig, Ana Anillo, Mireia Gea, Dolores Vilas, Lourdes Ispierto, Amaia Muñoz-Lopetegi, Gerard Mayà, Pau Pastor, Ramiro Álvarez, Joan Santamaria, Alex Iranzo, Katrin Beye. Peripheral α-synuclein isoforms are potential biomarkers for diagnosis and prognosis of isolated REM sleep behavior disorder. Parkinsonism & related disorders. vol 115. 2023-09-07. PMID:37678102. |
isolated rem sleep behavior disorder (irbd) represents an early manifestation of the synucleinopathies parkinson's disease (pd) and dementia with lewy bodies (dlb). |
2023-09-07 |
2023-10-07 |
Not clear |
| Jung-Ick Byun, Tae-Won Yang, Jun-Sang Sunwoo, Won Chul Shin, Oh-Young Kwon, Ki-Young Jun. Quantitative Network Comparisons of REM Sleep Without Atonia Across the α-Synucleinopathy Spectrum: A Systematic Review. Nature and science of sleep. vol 15. 2023-09-06. PMID:37670937. |
isolated rapid eye movement (rem) sleep behavior disorder (irbd) is characterized by rem sleep without atonia (rwa) and is regarded as the prodromal stage of α-synucleinopathies, such as parkinson's disease (pd), dementia with lewy bodies (dlb), and multiple system atrophy (msa). |
2023-09-06 |
2023-10-07 |
Not clear |
| Teruyuki Matsuoka, Jin Narumoto, Fukiko Morii-Kitani, Fumitoshi Niwa, Toshiki Mizuno, Mitsunari Abe, Harumasa Takano, Noritaka Wakasugi, Atsushi Shima, Nobukatsu Sawamoto, Hiroshi Ito, Wataru Toda, Takashi Hanakaw. Contribution of amyloid and putative Lewy body pathologies in neuropsychiatric symptoms. International journal of geriatric psychiatry. vol 38. issue 9. 2023-09-01. PMID:37655505. |
similarities and differences in the npss between preclinical/prodromal alzheimer's disease (ad) and prodromal parkinson's disease dementia (pdd)/dementia with lewy bodies (dlb) may exist. |
2023-09-01 |
2023-09-07 |
Not clear |
| John J Alam, Paul Maruff, Susan Doctrow, Hui-May Chu, Jennifer Conway, Stephen N Gomperts, Charlotte Teunisse. Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies. Neurology. 2023-09-01. PMID:37657939. |
in a proportion of patients, dementia with lewy bodies (dlb) is associated with alzheimer's disease (ad) co-pathology, which is linked to accelerated cognitive decline and more extensive cortical atrophy. |
2023-09-01 |
2023-09-07 |
Not clear |
| Olivier Bousiges, Benjamin Cretin, Candice Muller, Anne Botzung, Lea Sanna, Pierre Anthony, Nathalie Philippi, Catherine Demuynck, Frédéric Blan. Involvement of ApoE4 in dementia with Lewy bodies in the prodromal and demented stages: evaluation of the Strasbourg cohort. GeroScience. 2023-08-31. PMID:37653269. |
apoe4 as a risk factor for dementia with lewy bodies (dlb) is still an issue. |
2023-08-31 |
2023-09-07 |
human |
| Dylan J Dues, An Phu Tran Nguyen, Katelyn Becker, Jiyan Ma, Darren J Moor. Hippocampal subfield vulnerability to α-synuclein pathology precedes neurodegeneration and cognitive dysfunction. NPJ Parkinson's disease. vol 9. issue 1. 2023-08-28. PMID:37640722. |
cognitive dysfunction is a salient feature of parkinson's disease (pd) and dementia with lewy bodies (dlb). |
2023-08-28 |
2023-09-07 |
mouse |
| Asmus Vogel, Clara Mellergaard, Kristian Steen Frederikse. Different language profiles on neuropsychological tests in dementia with Lewy bodies and Alzheimer's disease. Applied neuropsychology. Adult. 2023-08-18. PMID:37595289. |
dementia with lewy bodies (dlb) and alzheimer's disease (ad) may lead to different cognitive profiles. |
2023-08-18 |
2023-10-07 |
Not clear |
| Noah J Graves, Yann Gambin, Emma Siereck. α-Synuclein Strains and Their Relevance to Parkinson's Disease, Multiple System Atrophy, and Dementia with Lewy Bodies. International journal of molecular sciences. vol 24. issue 15. 2023-08-12. PMID:37569510. |
in addition to pd, αsyn pathological aggregation is also detected in atypical parkinsonism, including dementia with lewy bodies (dlb), multiple system atrophy (msa), as well as neurodegeneration with brain iron accumulation, some cases of traumatic brain injuries, and variants of alzheimer's disease. |
2023-08-12 |
2023-08-16 |
Not clear |
| Irina A Skylar-Scott, Sharon J Sh. Lewy Body Dementia: An Overview of Promising Therapeutics. Current neurology and neuroscience reports. 2023-08-12. PMID:37572228. |
lewy body dementia (lbd) encompasses dementia with lewy bodies (dlb) and parkinson's disease dementia (pdd). |
2023-08-12 |
2023-08-16 |
Not clear |
| Zhenwei Yu, Ying Yang, Robin Barry Chan, Min Shi, Tessandra Stewart, Yang Huang, Zongran Liu, Guoyu Lan, Lifu Sheng, Chen Tian, Dishun Yang, Jing Zhan. GV-971 attenuates α-Synuclein aggregation and related pathology. CNS neuroscience & therapeutics. 2023-08-11. PMID:37563872. |
synucleinopathies, including parkinson's disease (pd), multiple system atrophy (msa), and dementia with lewy bodies (dlb), share a distinct pathological feature, that is, a widespread accumulation of α-synuclein (α-syn) in the brain. |
2023-08-11 |
2023-08-16 |
Not clear |
| Ji-Yun Cheng, Yue-Ting Deng, Jin-Tai Y. The causal role of circulating amino acids on neurodegenerative disorders: A two-sample Mendelian randomization study. Journal of neurochemistry. 2023-08-11. PMID:37565992. |
the potential causalities between nine amino acids (glutamine [glu], leucine [leu], isoleucine [ile], phenylalanine [phe], valine [val], alanine [ala], tyrosine [tyr], histidine [his], and glycine [gly]) and six neurodegenerative disorders (alzheimer's disease [ad], parkinson's disease [pd], multiple sclerosis [ms], frontotemporal dementia [ftd], lewy body dementia [dlb], amyotrophic lateral sclerosis [als]) were explored in this study. |
2023-08-11 |
2023-08-16 |
Not clear |
| Mariana Fernandes, Silvia Maio, Paolo Eusebi, Fabio Placidi, Francesca Izzi, Matteo Spanetta, Claudia De Masi, Clementina Lupo, Carmen Calvello, Marzia Nuccetelli, Sergio Bernardini, Nicola Biagio Mercuri, Claudio Liguor. CSF biomarkers for predicting phenoconversion in patients with isolated REM sleep behaviour disorder. Sleep. 2023-08-05. PMID:37542734. |
this study assessed cerebrospinal fluid (csf) biomarkers of neurodegeneration and blood-brain barrier (bbb) alteration in irbd patients compared to controls and ascertain whether these biomarkers may predict phenoconversion to alpha-synucleinopathies (parkinson's disease - pd, dementia with lewy bodies - dlb, multiple system atrophy - msa). |
2023-08-05 |
2023-08-14 |
Not clear |
| Magdalena I Tolea, Reem Ezzeddine, Simone Camacho, James E Galvi. Emerging drugs for dementia with Lewy bodies: A review of Phase II & III trials. Expert opinion on emerging drugs. 2023-08-02. PMID:37531299. |
despite faster cognitive decline and greater negative impact on patients and family caregivers, drug development efforts in dementia with lewy bodies (dlb) fall behind those for alzheimer's disease (ad). |
2023-08-02 |
2023-08-14 |
Not clear |
| Rory Durcan, Gemma Roberts, Calum A Hamilton, Paul C Donaghy, Kim Howe, Sean J Colloby, Louise M Allan, Michael Firbank, Sarah Lawley, George S Petrides, Jim J Lloyd, John-Paul Taylor, John T O'Brien, Alan J Thoma. Serial Nigrostriatal Dopaminergic Imaging in Mild Cognitive Impairment With Lewy Bodies, Alzheimer Disease, and Age-Matched Controls. Neurology. 2023-07-31. PMID:37524532. |
progressive nigrostriatal pathway degeneration occurs in patients with dementia with lewy bodies (dlb). |
2023-07-31 |
2023-08-14 |
Not clear |
| Yanaika S Hok-A-Hin, Katharina Bolsewig, Daimy N Ruiters, Alberto Lleó, Daniel Alcolea, Afina W Lemstra, Wiesje M van der Flier, Charlotte E Teunissen, Marta Del Camp. Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross-platform validation study. Alzheimer's & dementia (Amsterdam, Netherlands). vol 15. issue 3. 2023-07-28. PMID:37502019. |
our previous antibody-based cerebrospinal fluid (csf) proteomics study showed that thimet oligopeptidase (thop1), an amyloid beta (aβ) neuropeptidase, was increased in mild cognitive impairment with amyloid pathology (mci-aβ+) and alzheimer's disease (ad) dementia compared with controls and dementia with lewy bodies (dlb), highlighting the potential of csf thop1 as an early specific biomarker for ad. |
2023-07-28 |
2023-08-14 |
Not clear |
| Abhishek Lenka, Risa Isonaka, Courtney Holmes, David S Goldstei. Cardiac 18F-Dopamine Positron Emission Tomography Predicts the Type of Phenoconversion of Pure Autonomic Failure. Research square. 2023-07-28. PMID:37503103. |
clinically diagnosed paf can evolve ("phenoconvert") to a central lewy body disease (lbd, e.g., parkinson's disease (pd) or dementia with lewy bodies (dlb)) or to the non-lbd synucleinopathy multiple system atrophy (msa). |
2023-07-28 |
2023-08-14 |
Not clear |
| Yueyi Yu, Xinyi Xia, Xiaosheng Meng, Dan Li, Qi Qi. Plasma Phosphorylated Tau181 and Amyloid-β42 in Dementia with Lewy Bodies Compared with Alzheimer's Disease and Cognitively Healthy People. Journal of Alzheimer's disease : JAD. 2023-07-24. PMID:37482995. |
increasing evidence illustrates the value of plasma biomarkers of alzheimer's disease (ad) to screen for and identify dementia with lewy bodies (dlb). |
2023-07-24 |
2023-08-14 |
Not clear |
| Manabu Ikeda, Etsuro Mori, Satoshi Orimo, Tomomi Yamada, Osamu Konish. Efficacy of Adjunctive Therapy with Zonisamide Versus Increased Dose of Levodopa for Motor Symptoms in Patients with Dementia with Lewy Bodies: The Randomized, Controlled, Non-Inferiority DUEL Study. Journal of Alzheimer's disease : JAD. 2023-07-24. PMID:37483001. |
in patients with dementia with lewy bodies (dlb), it is unknown whether adjunct zonisamide is as effective and safe as increasing levodopa dose when levodopa has inadequate efficacy on parkinsonism. |
2023-07-24 |
2023-08-14 |
Not clear |
| Shuyu Zhang, Karina Dauer, Timo Strohäker, Lars Tatenhorst, Lucas Caldi Gomes, Simon Mayer, Byung Chul Jung, Woojin S Kim, Seung-Jae Lee, Stefan Becker, Friederike Liesche-Starnecker, Markus Zweckstetter, Paul Lingo. Alpha-synuclein fibrils amplified from multiple system atrophy and Parkinson's disease patient brain spread after intracerebral injection into mouse brain. Brain pathology (Zurich, Switzerland). 2023-07-24. PMID:37485772. |
parkinson's disease (pd), multiple system atrophy (msa), and dementia with lewy bodies (dlb) are neurodegenerative disorders with alpha-synuclein (α-syn) aggregation pathology. |
2023-07-24 |
2023-08-14 |
mouse |